Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#71 / 167 Total
USM - United States Cellular Corporation - Stock Price Chart
TickerUSM [NYSE]
CompanyUnited States Cellular Corporation
CountryUSA
IndustryTelecom Services
Market Cap2.91BEPS (ttm)0.64
P/E53.63EPS this Y29.69%
Forward P/E38.65EPS next Y7.99%
PEG4.97EPS past 5Y-18.48%
P/S0.74EPS next 5Y10.80%
P/B0.63EPS Q/Q148.30%
Dividend-Sales Q/Q-4.67%
Insider Own83.67%Inst Own17.91%
Insider Trans0.00%Inst Trans-3.03%
Short Float8.75%EarningsMay 03/b
Analyst Recom2.71Target Price46.00
Avg Volume213.95K52W Range13.79 - 48.47
United States Cellular Corp. engages in the provision of wireless telecommunication services. Its products include smartphones, tablets, vehicle routers, and accessories. It offers Internet plans, prepaid and postpaid plans, and roaming services. The company was founded by Leroy T. Carlson in 1983 and is headquartered in Chicago, IL.
SLNO - Soleno Therapeutics Inc - Stock Price Chart
TickerSLNO [NASD]
CompanySoleno Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap1.51BEPS (ttm)-2.98
P/E-EPS this Y33.76%
Forward P/E-EPS next Y51.81%
PEG-EPS past 5Y24.34%
P/S-EPS next 5Y15.00%
P/B9.07EPS Q/Q43.56%
Dividend-Sales Q/Q-
Insider Own39.22%Inst Own58.30%
Insider Trans-9.78%Inst Trans-0.96%
Short Float15.28%EarningsMar 06/a
Analyst Recom1.00Target Price64.33
Avg Volume382.25K52W Range3.48 - 53.82
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vivo Opportunity, LLC10% OwnerApr 30 '24Sale45.13351,24215,851,5517,316,851May 01 01:10 PM
Vivo Opportunity, LLC10% OwnerApr 29 '24Sale47.80750,00035,850,0007,668,093May 01 01:10 PM
Anish BhatnagarCHIEF EXECUTIVE OFFICERApr 01 '24Sale41.3418,980784,645152,790Apr 03 09:36 PM
Mackaness James HCHIEF FINANCIAL OFFICERApr 01 '24Sale41.345,175213,93762,953Apr 03 09:39 PM
Hirano Patricia CSEE REMARKSApr 01 '24Sale41.342,21891,69441,812Apr 03 09:37 PM
IDR - Idaho Strategic Resources Inc - Stock Price Chart
TickerIDR [AMEX]
CompanyIdaho Strategic Resources Inc
CountryUSA
IndustryGold
Market Cap95.58MEPS (ttm)0.09
P/E80.61EPS this Y200.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-0.08%
P/S7.00EPS next 5Y-
P/B5.31EPS Q/Q-45.70%
Dividend-Sales Q/Q10.06%
Insider Own16.68%Inst Own12.20%
Insider Trans0.00%Inst Trans5.61%
Short Float0.70%EarningsMar 25/b
Analyst Recom1.00Target Price10.00
Avg Volume37.01K52W Range4.48 - 9.70
Idaho Strategic Resources, Inc. engages in the exploration and development of gold, silver and base metal deposits. It has a portfolio of mineral properties namely: Golden Chest Mine, Murray Gold Belt, Butte Highlands and Central Idaho. The company was founded by Grant Brackebusch on July 18, 1996 and is headquartered in Coeur d'Alene, ID.
APDN - Applied Dna Sciences Inc - Stock Price Chart
TickerAPDN [NASD]
CompanyApplied Dna Sciences Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap3.23MEPS (ttm)-10.99
P/E-EPS this Y14.47%
Forward P/E-EPS next Y18.46%
PEG-EPS past 5Y45.52%
P/S0.36EPS next 5Y-
P/B0.61EPS Q/Q70.94%
Dividend-Sales Q/Q-83.07%
Insider Own12.32%Inst Own16.65%
Insider Trans0.00%Inst Trans-
Short Float1.78%EarningsFeb 08/a
Analyst Recom1.00Target Price45.00
Avg Volume12.98K52W Range3.60 - 37.20
Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment offers DNA detection via PCR to provide and develop clinical molecular diagnostics and genetic testing services. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
EXAI - Exscientia Plc ADR - Stock Price Chart
TickerEXAI [NASD]
CompanyExscientia Plc ADR
CountryUnited Kingdom
IndustryBiotechnology
Market Cap587.02MEPS (ttm)-1.46
P/E-EPS this Y5.07%
Forward P/E-EPS next Y1.18%
PEG-EPS past 5Y-116.17%
P/S23.46EPS next 5Y-
P/B1.29EPS Q/Q-9.42%
Dividend-Sales Q/Q-62.27%
Insider Own5.80%Inst Own19.04%
Insider Trans0.00%Inst Trans0.77%
Short Float3.70%EarningsMar 21/b
Analyst Recom2.67Target Price8.67
Avg Volume751.24K52W Range3.86 - 9.12
Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.
CGON - Cg Oncology Inc. - Stock Price Chart
TickerCGON [NASD, RUT]
CompanyCg Oncology Inc.
CountryUSA
IndustryBiotechnology
Market Cap2.42BEPS (ttm)-
P/E-EPS this Y-32.80%
Forward P/E-EPS next Y-20.35%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own38.60%Inst Own3.93%
Insider Trans2.66%Inst Trans-
Short Float6.85%Earnings-
Analyst Recom1.40Target Price66.80
Avg Volume552.30K52W Range28.55 - 50.23
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Decheng Capital Global Life Sc10% OwnerJan 29 '24Buy19.00400,0007,600,000400,000Jan 31 04:17 PM
Song Hong FangDirectorJan 29 '24Buy19.00263,1574,999,983613,928Jan 31 04:30 PM
Roche Corleen M.CFO & SecretaryJan 29 '24Buy19.002,00038,0002,000Jan 31 04:30 PM
Kasturi VijayChief Medical OfficerJan 29 '24Buy19.001,31524,9851,315Jan 31 04:30 PM
PESI - Perma-Fix Environmental Services, Inc. - Stock Price Chart
TickerPESI [NASD]
CompanyPerma-Fix Environmental Services, Inc.
CountryUSA
IndustryWaste Management
Market Cap159.94MEPS (ttm)0.03
P/E347.18EPS this Y-257.14%
Forward P/E5.91EPS next Y1900.00%
PEG-EPS past 5Y-
P/S1.78EPS next 5Y-
P/B4.05EPS Q/Q104.56%
Dividend-Sales Q/Q35.58%
Insider Own22.57%Inst Own25.60%
Insider Trans0.23%Inst Trans-0.05%
Short Float0.86%EarningsMar 13/b
Analyst Recom3.00Target Price5.00
Avg Volume67.76K52W Range6.51 - 14.17
Perma-Fix Environmental Services, Inc. is a nuclear services company, which engages in providing nuclear waste management services. It operates through the following segments: Treatment, Services, and Corporate. The Treatment segment includes nuclear, low-level radioactive, mixed hazardous and non-hazardous waste treatment, and processing and disposal services. The Services segment relates to on-site waste management services to commercial and government customers, technical services and nuclear services. The company was founded by Louis Francis Centofanti in December 1990 and is headquartered in Atlanta, GA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grondin RichardEVP of Waste Treatment OpsMar 26 '24Option Exercise5.5618,000100,05030,882Mar 27 04:30 PM
REEDER JOEDirectorJan 11 '24Option Exercise5.677,50042,525234,318Jan 12 12:21 PM
Lombardo AndyEVP of Nuclear & Technical SvcDec 05 '23Buy7.632,15016,40417,448Dec 06 08:30 AM
Duff MarkPresident and CEODec 01 '23Buy7.163,00021,465110,952Dec 04 08:18 AM
Shelton LarryDirectorDec 01 '23Buy7.202,00014,400167,162Dec 04 08:13 AM
OBIO - Orchestra BioMed Holdings Inc - Stock Price Chart
TickerOBIO [NASD, RUT]
CompanyOrchestra BioMed Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap182.53MEPS (ttm)-1.48
P/E-EPS this Y-8.41%
Forward P/E-EPS next Y-10.87%
PEG-EPS past 5Y-
P/S66.13EPS next 5Y-
P/B2.68EPS Q/Q-358.18%
Dividend-Sales Q/Q-
Insider Own37.91%Inst Own36.42%
Insider Trans0.00%Inst Trans-31.91%
Short Float3.75%EarningsMar 27/a
Analyst Recom1.00Target Price16.33
Avg Volume44.92K52W Range4.22 - 20.19
Apr-30-24 08:30AM Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents (GlobeNewswire)
08:00AM Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire)
Mar-27-24 04:17PM Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-26-24 08:00AM Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors (GlobeNewswire) +5.20%
Mar-13-24 08:00AM Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 08:00AM Orchestra BioMed to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.62%
Mar-06-24 08:37AM Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients (GlobeNewswire)
Feb-26-24 08:00AM Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years (GlobeNewswire)
Feb-16-24 09:13AM Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season (Zacks) -8.45%
Jan-08-24 07:30AM Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients (GlobeNewswire) +9.38%
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded on May 25, 2020 and is headquartered in New Hope, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSE ERIC A MDDirectorMay 17 '23Option Exercise1.082,3252,5112,325May 19 06:15 PM
Fain Eric SDirectorMay 10 '23Option Exercise1.082,9063,13829,767May 12 04:59 PM
DTSS - Datasea Inc - Stock Price Chart
TickerDTSS [NASD]
CompanyDatasea Inc
CountryChina
IndustrySoftware - Infrastructure
Market Cap289.33MEPS (ttm)-0.35
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-36.56%
P/S12.22EPS next 5Y-
P/B111.19EPS Q/Q9.42%
Dividend-Sales Q/Q2565.77%
Insider Own43.39%Inst Own0.36%
Insider Trans0.00%Inst Trans-83.55%
Short Float0.18%Earnings-
Analyst Recom1.00Target Price22.50
Avg Volume2.07M52W Range1.42 - 20.29
Datasea, Inc. is a technology company, which engages in the provision of smart security systems. It focuses on visual and non-visual fusion perception algorithms and big data analytics technologies, by providing customers with smart security solutions, smart hardware, education-related technologies applicable and 5G value-added services across multiple scenarios and industries. The company was founded by Zhi Xin Liu, Fu Liu, and Xing Zhong Sun on September 26, 2014, and is headquartered in Beijing, China.
ATMU - Atmus Filtration Technologies Inc - Stock Price Chart
TickerATMU [NYSE, RUT]
CompanyAtmus Filtration Technologies Inc
CountryUSA
IndustryPollution & Treatment Controls
Market Cap2.37BEPS (ttm)1.97
P/E14.46EPS this Y-3.89%
Forward P/E12.26EPS next Y4.46%
PEG28.92EPS past 5Y-
P/S1.45EPS next 5Y0.50%
P/B19.46EPS Q/Q-13.97%
Dividend-Sales Q/Q1.91%
Insider Own0.51%Inst Own35.04%
Insider Trans1.24%Inst Trans-
Short Float6.15%EarningsMay 03/b
Analyst Recom1.17Target Price34.83
Avg Volume4.14M52W Range18.21 - 33.70
Atmus Filtration Technologies, Inc. engages in the design, manufacture, and sale of filters, coolant, and chemical products. It offers products for first fit and aftermarket applications including air filters, fuel filters, fuel water separators, lube filters, hydraulic filters, coolants, and fuel additives. The company was founded in 1958 and is headquartered in Nashville, TN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Macadam Stephen E.DirectorNov 09 '23Buy19.495,200101,34819,268Nov 09 04:15 PM
134567891011121317